Dana dhuwit perusahaan Intellia Corp (NTLA)

Intellia Corp - logo grafis emiten NTLA

R&D pipeline dynamics drove the year's volatility, and the cash reserves on GURU.Markets reflect this momentum, where 0.48 shows the value of this parameter. The financial stability of Intellia Therapeutics (NTLA) is based on the commercialization of CRISPR drugs against ATTR, however, costly cryogenic transportation of biomaterials requires significant expenditures, making liquidity monitoring critical for the biotech startup's survival.

NTLA - Cadangan dhuwit perusahaan Intellia Corp ing rentang 04.07.2022 - 21.11.2026

Rincian metrik komprehensif lan analitis Intellia Therapeutics, Inc. (NTLA)

- rincian kapitalisasi pasar:
Analisis dhasar perusahaan:intelliatx.com
Sampel barang intelliatx.com

A stable liquidity reserve is critical for assessing the viability of the biotech sector, as it determines the funding horizon until product commercialization. By analyzing the current cash position, an investor tracks the absolute volume of funds to hedge against bankruptcy, which for Intellia Therapeutics (NTLA) ensures the development of proprietary CRISPR technologies and the protection of patent barriers during costly clinical trials.

Pesaing Intellia Therapeutics

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Stoke - Dhuwit awis perusahaan|BLFS: Dhuwit awis lan setara dhuwit awis perusahaan|Wave Life Sciences Corp - Volume dana dhuwit perusahaan|Maze Therapeutics, Inc. (MAZE) - Dhuwit awis perusahaan|Sionna Therapeutics Inc (SION) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Prime Medicine Corp|Dana dhuwit perusahaan tayshagtx.com|QURE - Posisi dhuwit perusahaan|Dhuwit awis perusahaan MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Posisi dhuwit perusahaan|Volume dana dhuwit perusahaan SLDB (Solid Biosciences Inc.)|Sisa dhuwit perusahaan OCGN|PacBio Corp - Volume dana dhuwit perusahaan|Benitec Biopharma Inc. (BNTC) - Dhuwit awis perusahaan|DSGN: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan RCKT|Dhuwit awis perusahaan FDMT|Dhuwit awis lan setara dhuwit awis perusahaan LXEO (Lexeo Therapeutics)|Volume dana dhuwit perusahaan KRRO|Editas Medicine, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Silence Therapeutics Inc. SLN|Volume dana dhuwit perusahaan ProQR Therapeutics N.V. PRQR|CDXS: Dhuwit awis perusahaan|Posisi dhuwit perusahaan Sangamo (SGMO)|NAUT (Nautilus Bio) - Dhuwit awis perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan